JP2008512108A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008512108A5 JP2008512108A5 JP2007530803A JP2007530803A JP2008512108A5 JP 2008512108 A5 JP2008512108 A5 JP 2008512108A5 JP 2007530803 A JP2007530803 A JP 2007530803A JP 2007530803 A JP2007530803 A JP 2007530803A JP 2008512108 A5 JP2008512108 A5 JP 2008512108A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- agent
- sbn
- polypeptide
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 241000191967 Staphylococcus aureus Species 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 230000003993 interaction Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- 239000000589 Siderophore Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- -1 However Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-Serine Natural products OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 claims 1
- VZXPDPZARILFQX-BYPYZUCNSA-N O-acetyl-L-serine Chemical compound CC(=O)OC[C@H]([NH3+])C([O-])=O VZXPDPZARILFQX-BYPYZUCNSA-N 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 101100309556 Staphylococcus aureus (strain NCTC 8325 / PS 47) sbnB gene Proteins 0.000 claims 1
- 101100309557 Staphylococcus aureus (strain NCTC 8325 / PS 47) sbnC gene Proteins 0.000 claims 1
- 101100309558 Staphylococcus aureus (strain NCTC 8325 / PS 47) sbnD gene Proteins 0.000 claims 1
- 101100309559 Staphylococcus aureus (strain NCTC 8325 / PS 47) sbnE gene Proteins 0.000 claims 1
- 101100309560 Staphylococcus aureus (strain NCTC 8325 / PS 47) sbnF gene Proteins 0.000 claims 1
- 101100309561 Staphylococcus aureus (strain NCTC 8325 / PS 47) sbnH gene Proteins 0.000 claims 1
- 101100309562 Staphylococcus aureus (strain NCTC 8325 / PS 47) sbnI gene Proteins 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 229960001153 serine Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60789604P | 2004-09-08 | 2004-09-08 | |
| PCT/IB2005/004081 WO2006043182A2 (en) | 2004-09-08 | 2005-09-08 | Screening assays for inhibitors of a staphylococcus aureus siderophore |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008512108A JP2008512108A (ja) | 2008-04-24 |
| JP2008512108A5 true JP2008512108A5 (enExample) | 2008-10-16 |
Family
ID=36203330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007530803A Pending JP2008512108A (ja) | 2004-09-08 | 2005-09-08 | スタフィロコッカス−アウレウス−シデロフォアの阻害剤のスクリーニング検定 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110206685A1 (enExample) |
| EP (1) | EP1786907A4 (enExample) |
| JP (1) | JP2008512108A (enExample) |
| KR (1) | KR20070083638A (enExample) |
| AU (1) | AU2005297171A1 (enExample) |
| CA (1) | CA2576643A1 (enExample) |
| WO (1) | WO2006043182A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8637657B2 (en) | 2008-08-19 | 2014-01-28 | David E. Heinrichs | Siderophore-mediated iron uptake in bacterial infection |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994000868A1 (en) * | 1992-06-26 | 1994-01-06 | Materials Research Corporation | Transport system for wafer processing line |
| AU2002306849A1 (en) * | 2001-03-21 | 2002-10-08 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| GB0107661D0 (en) * | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| AU2002353764A1 (en) * | 2001-06-17 | 2003-03-18 | D-Squared Biotechnologies, Inc. | Staphylococci surface-exposed immunogenic polypeptides |
| US6605459B2 (en) * | 2001-07-13 | 2003-08-12 | Paradigm Genetics, Inc. | Methods for measuring cysteine and determining cysteine synthase activity |
| US20040029129A1 (en) * | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
-
2005
- 2005-09-08 EP EP05849653A patent/EP1786907A4/en not_active Withdrawn
- 2005-09-08 US US11/574,959 patent/US20110206685A1/en not_active Abandoned
- 2005-09-08 AU AU2005297171A patent/AU2005297171A1/en not_active Abandoned
- 2005-09-08 JP JP2007530803A patent/JP2008512108A/ja active Pending
- 2005-09-08 WO PCT/IB2005/004081 patent/WO2006043182A2/en not_active Ceased
- 2005-09-08 CA CA002576643A patent/CA2576643A1/en not_active Abandoned
- 2005-09-08 KR KR1020077007982A patent/KR20070083638A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006519605A5 (enExample) | ||
| Kostura et al. | Purification and activation of the double-stranded RNA-dependent eIF-2 kinase DAI | |
| JP2008546390A5 (enExample) | ||
| Choudhary et al. | Respiratory syncytial virus influences NF-κB-dependent gene expression through a novel pathway involving MAP3K14/NIK expression and nuclear complex formation with NF-κB2 | |
| Yao et al. | Hybridization assay of hepatitis B virus by QCM peptide nucleic acid biosensor | |
| JP2008520242A5 (enExample) | ||
| CN115175685B (zh) | 用于治疗血管生成素样4(angptl4)相关疾病的寡核苷酸 | |
| JP2006500949A5 (enExample) | ||
| JP2013528372A5 (enExample) | ||
| JPWO2013129603A1 (ja) | Ｔｄｐ−４３細胞内存在量関連疾患の認定方法 | |
| JP2008517900A5 (enExample) | ||
| JP2018148886A (ja) | Ｃｄｋ阻害剤と関連するバイオマーカー | |
| RU2006143156A (ru) | Gm3 синтаза как терапевтическая мишень при капиллярных осложнениях диабета | |
| JP2008512984A5 (enExample) | ||
| JP2010507666A5 (enExample) | ||
| CN106544342A (zh) | Mt2a基因组蛋白乙酰化修饰检测试剂盒及引物对 | |
| JP6095889B2 (ja) | 染色体２１ｑ、６ｑ、および１５ｑの遺伝子変異およびこれらを使用して１型糖尿病を診断および治療する方法 | |
| JP2005534308A5 (enExample) | ||
| US11634717B2 (en) | DNA aptamer specifically binding to TB7.7, and use thereof | |
| JP2006503575A5 (enExample) | ||
| Thirumalai et al. | Disposable microRNA biosensors based on dual-role polymer-dispersed silver nanowires for diagnosis of viral hemorrhagic septicemia virus infection in olive flounder | |
| CN118632711A (zh) | 因子h家族蛋白的抑制性核酸 | |
| JP2005525097A5 (enExample) | ||
| US20180016582A1 (en) | Dna aptamer binding to non-small cell lung cancer cells (h1975) | |
| WO2008092262A1 (en) | Methods and compounds for treatment, prevention and diagnosis of parasitic infection and disease |